Literature DB >> 25937764

Advances in chemotherapy for pancreatic cancer.

Bhawna Sirohi1, Ashish Singh2, Shaheenah Dawood3, Shailesh V Shrikhande4.   

Abstract

Pancreatic cancer remains challenging to treat. Over the past decade, there have been some major improvements in systemic therapy. Gemcitabine remains the key drug for both early and advanced cancer but combination chemotherapy is emerging as a new paradigm for patients with good performance status. This review focuses on current chemotherapy status for patients with pancreatic cancer.

Entities:  

Keywords:  FOLFIRINOX; Gemcitabine; Nab-Paclitaxel; Pancreatic cancer

Year:  2015        PMID： 25937764      PMCID： PMC4412866          DOI： 10.1007/s13193-014-0371-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  79 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Authors:  Kathleen K Christians; Susan Tsai; Anna Mahmoud; Paul Ritch; James P Thomas; Lauren Wiebe; Tracy Kelly; Beth Erickson; Huamin Wang; Douglas B Evans; Ben George
Journal:  Oncologist       Date:  2014-02-25

3.  Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.

Authors:  Michael D Chuong; Tom J Hayman; Manish R Patel; Mark S Russell; Mokenge P Malafa; Pamela J Hodul; Gregory M Springett; Junsung Choi; Ravi Shridhar; Sarah E Hoffe
Journal:  Gastrointest Cancer Res       Date:  2011-07

4.  Borderline resectable pancreatic tumors: is there a need for further refinement of this stage?

Authors:  Shailesh V Shrikhande; Supreeta Arya; Savio George Barreto; Sachin Ingle; Melroy A D'Souza; Rohini Hawaldar; Parul J Shukla
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-06

5.  Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.

Authors:  Jae-Lyun Lee; Song Cheol Kim; Ji-Hoon Kim; Sang Soo Lee; Tae-Won Kim; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Myung-Hwan Kim; Jong Hoon Kim; Jin-Hong Park; Sang Hyun Shin; Duck Jong Han
Journal:  Surgery       Date:  2012-06-06       Impact factor: 3.982

6.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Authors:  Giuseppe Colucci; Roberto Labianca; Francesco Di Costanzo; Vittorio Gebbia; Giacomo Cartenì; Bruno Massidda; Elisa Dapretto; Luigi Manzione; Elena Piazza; Mirella Sannicolò; Marco Ciaparrone; Luigi Cavanna; Francesco Giuliani; Evaristo Maiello; Antonio Testa; Paolo Pederzoli; Massimo Falconi; Ciro Gallo; Massimo Di Maio; Francesco Perrone
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 7.  Advanced or metastatic pancreatic cancer: molecular targeted therapies.

Authors:  Soley Bayraktar; Caio M Rocha-Lima
Journal:  Mt Sinai J Med       Date:  2010 Nov-Dec

8.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

9.  Pancreatic cancer with distant metastases: a contraindication for radical surgery?

Authors:  Suguru Yamada; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Hideki Kasuya; Shuji Nomoto; Shin Takeda; Yasuhiro Kodera; Akimasa Nakao
Journal:  Hepatogastroenterology       Date:  2009 May-Jun

10.  Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

Authors:  Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544
View more
  3 in total

1.  EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.

Authors:  Amit Singh; Jing Xu; George Mattheolabakis; Mansoor Amiji
Journal:  Nanomedicine       Date:  2015-12-03       Impact factor: 5.307

2.  Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy.

Authors:  Yang Chen; Cejun Yang; Juan Mao; Haigang Li; Jinsong Ding; Wenhu Zhou
Journal:  RSC Adv       Date:  2019-04-09       Impact factor: 4.036

3.  Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.

Authors:  Xiang Li; Chengxiang Guo; Qinghai Li; Shumei Wei; Qi Zhang; Yiwen Chen; Yinan Shen; Tao Ma; Guogang Li; Shunliang Gao; Risheng Que; Jianying Lou; Risheng Yu; Ying Yuan; Qichun Wei; Pintong Huang; Tingbo Liang; Xueli Bai
Journal:  Oncologist       Date:  2018-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.